Haemonetics Corporation (HAE): Price and Financial Metrics

Haemonetics Corporation (HAE): $84.84

1.58 (+1.90%)

POWR Rating

Component Grades








HAE Price/Volume Stats

Current price $84.84 52-week high $95.26
Prev. close $83.26 52-week low $72.26
Day low $82.80 Volume 226,600
Day high $84.89 Avg. volume 318,796
50-day MA $86.34 Dividend yield N/A
200-day MA $85.61 Market Cap 4.30B

HAE Stock Price Chart Interactive Chart >


  • Quality is the dimension where HAE ranks best; there it ranks ahead of 86.92% of US stocks.
  • HAE's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • HAE ranks lowest in Momentum; there it ranks in the 10th percentile.

HAE Stock Summary

  • HAE's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 125.51 -- higher than 79.34% of US-listed equities with positive expected earnings growth.
  • HAE's went public 32.59 years ago, making it older than 84.3% of listed US stocks we're tracking.
  • The volatility of HAEMONETICS CORP's share price is greater than that of only 6.06% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to HAEMONETICS CORP, a group of peers worth examining would be CMCO, XGN, XRX, LXFR, and MTRN.
  • HAE's SEC filings can be seen here. And to visit HAEMONETICS CORP's official web site, go to www.haemonetics.com.

HAE Valuation Summary

  • HAE's price/earnings ratio is 32.8; this is 23.54% higher than that of the median Healthcare stock.
  • Over the past 243 months, HAE's EV/EBIT ratio has gone up 13.3.

Below are key valuation metrics over time for HAE.

Stock Date P/S P/B P/E EV/EBIT
HAE 2023-11-20 3.4 4.7 32.8 27.6
HAE 2023-11-17 3.4 4.7 32.9 27.7
HAE 2023-11-16 3.7 5.1 35.3 29.5
HAE 2023-11-15 3.7 5.1 35.3 29.5
HAE 2023-11-14 3.7 5.1 35.4 29.5
HAE 2023-11-13 3.5 4.9 34.3 28.7

HAE Growth Metrics

    The 3 year cash and equivalents growth rate now stands at 53.23%.
  • Its 3 year net income to common stockholders growth rate is now at -21.16%.
  • Its 5 year net income to common stockholders growth rate is now at 391.33%.
HAE's revenue has moved up $243,130,000 over the prior 70 months.

The table below shows HAE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 1,129.246 261.497 95.759
2022-09-30 1,083.714 259.515 86.047
2022-06-30 1,026.126 215.936 67.706
2022-03-31 993.196 172.263 43.375
2021-12-31 953.223 105.76 22.593
2021-09-30 933.825 109.618 31.243

HAE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HAE has a Quality Grade of C, ranking ahead of 50% of graded US stocks.
  • HAE's asset turnover comes in at 0.569 -- ranking 76th of 186 Medical Equipment stocks.
  • CRY, CTSO, and CSII are the stocks whose asset turnover ratios are most correlated with HAE.

The table below shows HAE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-07-03 0.569 0.460 0.072
2021-04-03 0.581 0.457 0.090
2020-12-26 0.650 0.486 0.150
2020-09-26 0.674 0.485 0.151
2020-06-27 0.738 0.485 0.142
2020-03-28 0.798 0.490 0.116

HAE Price Target

For more insight on analysts targets of HAE, see our HAE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $79.25 Average Broker Recommendation 1.38 (Strong Buy)

Haemonetics Corporation (HAE) Company Bio

Haemonetics designs, manufactures, and markets blood management solutions. The Company serves in three markets, such as manufacturers of plasma-derived pharmaceuticals, blood collectors, and hospitals. The company was founded in 1971 and is based in Braintree, Massachusetts.

HAE Latest News Stream

Event/Time News Detail
Loading, please wait...

HAE Latest Social Stream

Loading social stream, please wait...

View Full HAE Social Stream

Latest HAE News From Around the Web

Below are the latest news stories about HAEMONETICS CORP that investors may wish to consider to help them evaluate HAE as an investment opportunity.

BrainsWay (BWAY) Strengthens South Korean Foothold With Deep TMS

BrainsWay's (BWAY) Deep TMS targets affected brain structures with a magnetic field, stimulating crucial neural networks.

Yahoo | December 8, 2023

Quest Diagnostics (DGX) & CDC to Assess Hepatitis C Burden

Quest Diagnostics (DGX) and CDC expand research collaboration to better understand the Hepatitis C burden in the United States.

Yahoo | December 8, 2023

Haemonetics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 9:45am Pacific time.

Yahoo | December 7, 2023

Here's Why You Should Retain Boston Scientific (BSX) Now

Investors are optimistic about Boston Scientific (BSX) on strong worldwide demand for its GI and pulmonary treatment options and traction in Europe for its next-generation WATCHMAN FLX.

Yahoo | December 7, 2023

Globus Medical (GMED) Gains From NuVasive Deal, Macro Woes Stay

Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Yahoo | December 7, 2023

Read More 'HAE' Stories Here

HAE Price Returns

1-mo -0.86%
3-mo -4.11%
6-mo -3.10%
1-year 5.86%
3-year -26.36%
5-year -18.58%
YTD 7.87%
2022 48.28%
2021 -55.33%
2020 3.35%
2019 14.84%
2018 72.26%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!